Penumbra Q4 adjusted revenue $321.3M (+13%); U.S. thrombectomy up 27%

Penumbra Inc

2024-FY EPS reported $0.36 revenue$1,194,615,000

Adjusted revenue (excl. Italian payback) Q4 $321.3M, up 12.9% YoY; reported revenue $315.5M (+10.8%).
GAAP net income Q4 $33.7M (10.7% margin); full-year net income $14.0M.
Adjusted EBITDA Q4 $63.7M (19.8% margin); full-year $171.0M (14.2% margin).
U.S. thrombectomy products grew 27.3% in Q4; international thrombectomy revenue declined 13.9% adjusted.
Full-year adjusted revenue $1,200.4M, up 13.4% YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.